insight
✂️ 성형 🏥 중증 🌐 전체
← 뒤로

Neoadjuvant Immunochemotherapy for Stage II-IIIB Non-Small Cell Lung Cancer With Mutations Beyond EGFR 19del, L858R, and ALK Rearrangement.

1/5 보강
The Annals of thoracic surgery 📖 저널 OA 6.1% 2023: 0/1 OA 2025: 0/10 OA 2026: 2/45 OA 2023~2026 2025 Vol.120(6) p. 1052-1061
Retraction 확인
출처
PubMed DOI

PICO 자동 추출 (휴리스틱, conf 3/4)

유사 논문
P · Population 대상 환자/모집단
24 patients received neoICT and neoChT, respectively.
I · Intervention 중재 / 시술
neoICT or neoChT followed by curative-intent resection were retrospectively enrolled between November 2019 and August 2023
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
In the neoICT group, nonadenocarcinoma histologic features and elevated programmed cell death ligand 1 levels were correlated with higher MPR rates. [CONCLUSIONS] NeoICT resulted in superior pathologic response and survival compared with neoChT in both KRAS-mutant and non-KRAS-mutant subgroups.

Ding H, Tao B, Xu L, Jiang G, Wang H

PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓
📝 환자 설명용 한 줄

[BACKGROUND] Neoadjuvant immunochemotherapy (neoICT) is not currently recommended for patients with stage II-IIIB non-small cell lung cancer (NSCLC) harboring oncogenic driver mutations, especially ty

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • p-value P = .012
  • 95% CI 0.14-0.80

이 논문을 인용하기

↓ .bib ↓ .ris
APA Ding H, Tao B, et al. (2025). Neoadjuvant Immunochemotherapy for Stage II-IIIB Non-Small Cell Lung Cancer With Mutations Beyond EGFR 19del, L858R, and ALK Rearrangement.. The Annals of thoracic surgery, 120(6), 1052-1061. https://doi.org/10.1016/j.athoracsur.2025.04.016
MLA Ding H, et al.. "Neoadjuvant Immunochemotherapy for Stage II-IIIB Non-Small Cell Lung Cancer With Mutations Beyond EGFR 19del, L858R, and ALK Rearrangement.." The Annals of thoracic surgery, vol. 120, no. 6, 2025, pp. 1052-1061.
PMID 40339974 ↗
DOI 10.1016/j.athoracsur.2025.04.016

Abstract

[BACKGROUND] Neoadjuvant immunochemotherapy (neoICT) is not currently recommended for patients with stage II-IIIB non-small cell lung cancer (NSCLC) harboring oncogenic driver mutations, especially tyrosine kinase inhibitor-sensitizing epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK). This study aimed to compare the pathologic response and survival outcomes between neoICT and neoadjuvant chemotherapy (neoChT) in patients with stage II-IIIB NSCLC harboring driver mutations beyond EGFR exon 19 deletion (19del), exon 21 L858R, and ALK rearrangement.

[METHODS] Patients with stage II-IIIB NSCLC harboring driver mutations (EGFR 20ins/EGFR G719X/KRAS/BRAF/c-MET/HER-2/ROS1/RET/PIK3CA) who underwent neoICT or neoChT followed by curative-intent resection were retrospectively enrolled between November 2019 and August 2023. Kaplan-Meier analysis was performed to evaluate recurrence-free survival (RFS). Multivariable Cox proportional hazards regression was used to identify factors influencing survival outcomes after propensity score matching (2:1).

[RESULTS] A total of 52 and 24 patients received neoICT and neoChT, respectively. Kirsten rat sarcoma virus (KRAS) mutations were detected in 67.1% (51 of 76) of patients. The major pathologic response (MPR) rates were 53.8% and 4.2%, respectively. NeoICT conferred better RFS than neoChT (2-year RFS rate: 79.5% vs 49.9%; log-rank P = .012). After matching, multivariable Cox proportional hazards regression demonstrated that neoICT was associated with improved RFS compared with neoChT (hazard ratio, 0.33; 95% CI, 0.14-0.80). Similar findings were observed in both the KRAS-mutant and non-KRAS-mutant subgroups. In the neoICT group, nonadenocarcinoma histologic features and elevated programmed cell death ligand 1 levels were correlated with higher MPR rates.

[CONCLUSIONS] NeoICT resulted in superior pathologic response and survival compared with neoChT in both KRAS-mutant and non-KRAS-mutant subgroups.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반